Connect with us

Technology

Reimagining our urban futures: Health-Driven Design for Cities (HD4) research programme launches in Singapore

Published

on

SINGAPORE, Dec. 9, 2024 /PRNewswire/ — December sees the launch of Health-Driven Design for Cities (HD4), a groundbreaking Singapore-based research collaboration seeking to discover how best to design urban environments that enhance the health of their residents.

HD4 is a partnership between Nanyang Technological University, Singapore (NTU Singapore) the National University of Singapore (NUS), and the University of Cambridge. It has received funding from the National Research Foundation, Singapore, and is hosted and co-led by the Cambridge Centre for Advanced Research and Education in Singapore (CARES).

Health challenges of urbanisation

Cities around the world face increasing challenges in managing issues such as heat islands, noise and air pollution, stress, and limited access to healthy food and physical activity. These environmental factors contribute to a growing burden of non-communicable diseases (NCDs), such as diabetes, obesity, cancer and cardiac disease. With urban populations growing rapidly around the world, there is an urgent need to rethink how cities are designed to promote health and well-being.

Prof Nick Wareham, HD4 Programme Lead at the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge said:

“As a city with ambitious plans for improving its citizens’ health, and a burgeoning research sector and rich health data, Singapore offers a unique setting for this work. HD4 will not only be studying the challenges of a growing city in the twenty-first century, but doing so in a city eager to implement strategies and tools to address them.”

International, interdisciplinary team

The HD4 programme brings together a world-class team of epidemiologists, clinicians, scientists, engineers, and architects. They will investigate how individuals live and move in Singapore, how the urban environment shapes their exposure to health risks, and how this influences their behaviour and health.

A key element in this process is HD4’s collaboration with Singapore’s SG100K cohort study, which is analysing the factors influencing NCDs in a representative and fully consented sample of 100,000 Singaporeans. All data that HD4 will analyse is fully de-identified and securely processed.

Professor of Cardiovascular Epidemiology (President’s Chair), John Chambers, Programme Lead of the HD4 Programme and SG100K study at NTU Singapore’s Lee Kong Chian School of Medicine, said:

“By integrating environmental data with the health and behavioural data from SG100K, this research will deepen our understanding of how environmental and social factors shape health outcomes, and how we might change the built environment to reduce health risks and burdens.”  

Interlocking research for a healthier Singapore

HD4 will undertake research in the following key areas:

characterising the features of the environment that potentially impact health in Singaporeunderstanding the links between environmental factors, individual behaviour and health outcomesobserving the impact of environmental change on health in Singaporesimulating the impact of potential changes on the health of Singaporeansworking with government agencies to co-develop data-rich public health tools

HD4 co-leads Dr Ronita Bardhan (University of Cambridge) and Dr Rudi Stouffs (NUS College of Design and Engineering), said:

“This project will develop the science of connecting the environment with health at multiple scales, from how individual Singaporeans experience the city, to how planners and policymakers shape our urban futures. The techniques, technologies, tools and knowledge gained through the programme will create a comprehensive system-level view of how the environment affects population health.”

HD4 will provide the basis for a data-rich public health approach, and through partnership with government agencies will ensure that findings can be translated into actionable policy recommendations that can guide Singapore’s urban planning and health strategies in the years ahead.

Learning from this programme also promises to be valuable to those shaping sustainable and health-focused cities the world over. The programme also promises to enrich Singapore’s research ecosystem by training the next generation of researchers, equipped with both local expertise and international perspectives.

About CARES

The Cambridge Centre for Advanced Research and Education (CARES) was established in 2013 as the University of Cambridge’s first overseas research centre, bringing together researchers from Cambridge, Nanyang Technological University, and the National University of Singapore as part of the CREATE (Campus for Research Excellence and Technological Enterprise) programme. The flagship programme at CARES is the Centre for Carbon Reduction in Chemical Technology (C4T) programme which focuses on decarbonising Singapore’s chemical industry and expanded in recent years to include additional themes such as digital transformation, and sectors such as the maritime industry.

A further large programme began in October 2020 called the Centre for Lifelong Learning and Individualised Cognition (CLIC), bringing together researchers from Cambridge and NTU to focus on the science of learning. CARES recently launched two projects on hydrogen and ammonia combustion (HYCOMBS) and the sustainable manufacturing of molecules and materials (SM3), as part of a large Decarbonisation programme announced in July 2024, supported by the National Research Foundation in Singapore.

www.cares.cam.ac.uk    LinkedIn: Cambridge CARES

About CREATE (Campus for Research Excellence and Technological Enterprise)

CREATE is an international collaboratory housing research centres set up by top universities. At CREATE, researchers from diverse disciplines and backgrounds work closely together to perform cutting-edge research in strategic areas of interest, for translation into practical applications leading to positive economic and societal outcomes for Singapore. The interdisciplinary research centres at CREATE focus on four areas of interdisciplinary thematic areas of research, namely human systems, energy systems, environmental systems and urban systems.

More information on the CREATE programme can be obtained from www.create.edu.sg.

About the Medical Research Council (MRC) Epidemiology Unit

The MRC Epidemiology Unit is a department at the University of Cambridge. It is working to improve the health of people in the UK and around the world. Obesity, type 2 diabetes and related metabolic disorders present a major and growing global public health challenge. These disorders result from a complex interplay between genetic, developmental, behavioural and environmental factors that operate throughout life. The mission of the Unit is to investigate the individual and combined effects of these factors and to develop and evaluate strategies to prevent these diseases and their consequences.
www.mrc-epid.cam.ac.uk

View original content:https://www.prnewswire.com/apac/news-releases/reimagining-our-urban-futures-health-driven-design-for-cities-hd4-research-programme-launches-in-singapore-302325733.html

SOURCE Cambridge Centre for Advanced Research and Education in Singapore

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MATSON ANNOUNCES ADDITION OF 3 MILLION SHARES TO EXISTING SHARE REPURCHASE PROGRAM AND QUARTERLY DIVIDEND OF $0.36 PER SHARE

Published

on

By

HONOLULU, April 23, 2026 /PRNewswire/ — The Board of Directors of Matson, Inc. (NYSE: MATX), a leading U.S. carrier in the Pacific, approved adding three million shares to its existing share repurchase program and extending the program to December 31, 2029.  As of April 23, 2026, the existing share repurchase program had approximately 0.7 million shares remaining.  The Board also declared a second quarter dividend of $0.36 per common share.  The dividend will be paid on June 4, 2026 to all shareholders of record as of the close of business on May 7, 2026.

“We are pleased to announce an additional three million shares to our existing share repurchase program,” said Matt Cox, Matson’s Chairman and Chief Executive Officer.  “Since we commenced our share repurchase program in August 2021, we have repurchased approximately 14.3 million shares, or approximately 33% of the then outstanding shares, for a total cost of $1.3 billion.  Going forward, we will continue to be both disciplined and opportunistic in our capital allocation, and we remain committed to returning excess cash to shareholders to create additional shareholder value over the long-term.” 

Shares will be repurchased in the open market from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its common shares and general market conditions.  The Company may enter into Rule 10b5-1 plans to facilitate purchases under the program.  The repurchase program may be suspended or discontinued at any time.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services.  Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia.  Matson also operates premium, expedited services from China to Long Beach, California, which includes cargo from other Asia origins, provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia.  The Company’s fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges.  Matson Logistics, established in 1987, extends the geographic reach of Matson’s transportation network throughout North America and Asia.  Its integrated logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska.  Additional information about the Company is available at www.matson.com.

Forward Looking Statements

Statements in this news release that are not historical facts are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to, statements about capital allocation plans, the timing, manner and volume of repurchases of common shares pursuant to the repurchase program, and use of excess cash.  These forward-looking statements are not guarantees of future performance.  This release should be read in conjunction with our Annual Report on Form 10-K and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release.  We do not undertake any obligation to update our forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/matson-announces-addition-of-3-million-shares-to-existing-share-repurchase-program-and-quarterly-dividend-of-0-36-per-share-302752377.html

SOURCE Matson, Inc.

Continue Reading

Technology

Accord Specialty Pharmacy Named Finalist in MMIT’s 11th Annual Retail Specialty Pharmacy Patient Choice Awards

Published

on

By

ORLANDO, Fla., April 23, 2026 /PRNewswire/ — Accord Specialty Pharmacy, an independent specialty pharmacy serving patients across multiple states, has been named a finalist in the MMIT Patient Choice Awards, a recognition based on patient-reported satisfaction and experience.

Accord was selected as the only independent pharmacy among finalists in its category, alongside national pharmacy organizations such as Walgreens Specialty Pharmacy and Walmart Specialty Pharmacy. This distinction highlights the company’s commitment to delivering personalized, high-touch care for patients managing complex and chronic conditions.

The MMIT Patient Choice Awards recognize specialty pharmacies that demonstrate excellence in patient satisfaction, service quality, and overall care experience. Finalists are determined based on direct patient feedback, making the recognition a meaningful reflection of the trust patients place in their pharmacy providers.

“Being recognized alongside national organizations and as the only independent finalist validates our belief that personalized, patient-centered care drives better outcomes. We are building a model that combines clinical depth, national reach, and operational flexibility to better serve patients, providers, and partners.” said AJ Patel, Founder and Pharmacy Manager of Accord Specialty Pharmacy.

Accord Specialty Pharmacy supports patients across complex specialty categories, including oncology, rare disease, and infusion, through a clinically driven, high-touch care model designed to improve access, adherence, and outcomes. The company’s approach emphasizes personalized support, responsive care coordination, and strong clinical engagement to help patients navigate complex therapies more effectively. With a growing national footprint and multi-state licensure, Accord is positioned to support patients, providers, and partners across diverse markets.

For more information, visit MMIT Announces Finalists of the 11th Specialty Pharmacy Patient Choice Awards – MMITNetwork.

About Accord Specialty Pharmacy:

Accord Specialty Pharmacy is an ACHC-accredited, multi-state licensed independent specialty pharmacy located in Central Florida, dedicated to delivering high-quality, patient-centered care for individuals managing complex and chronic conditions. Through personalized support, clinical expertise, and a high-touch approach, Accord helps patients navigate every step of their treatment journey. Learn more at www.accordspecialty.com.

CONTACT: contact@accordspecialty.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-specialty-pharmacy-named-finalist-in-mmits-11th-annual-retail-specialty-pharmacy-patient-choice-awards-302752327.html

SOURCE Accord Specialty

Continue Reading

Technology

HAIVISION ANNOUNCES VOTING RESULTS FROM 2026 ANNUAL MEETING OF SHAREHOLDERS

Published

on

By

MONTRÉAL, April 23, 2026 /CNW/ – Haivision Systems Inc. (“Haivision” or the “Company”) (TSX: HAI) is pleased to announce the voting results from its annual meeting of shareholders held today in a virtual format.

A total of approximately 45.97 % of the issued and outstanding common shares of Haivision were represented at the meeting.

Election of Directors

Each of the six nominated directors of Haivision was elected as director of the Company with the following results:

Director

Votes
For

% Votes
For

Votes
Against

% Votes
Against

Miroslav Wicha

11,110,245

99.26 %

82,583

0.74 %

Harvey Bienenstock

11,155,137

99.66 %

37,691

0.34 %

Robin M. Rush

11,121,855

99.37 %

70,973

0.63 %

Neil Hindle

10,794,005

96.44 %

398,823

3.56 %

Julie Tremblay

10,941,969

97.76 %

250,859

2.24 %

Lee K. Levy II

9,084,418

81.16 %

2,108,410

18.84 %

2.   Appointment of Auditors

Deloitte LLP were reappointed auditors of the Company for the ensuing year with 12,492,582 (98.84%) votes cast in favour and 146,406 (1.16%) votes withheld.

3.   Approval of the Unallocated Awards under the Company’s Equity Incentive Plan

The Company’s unallocated awards were approved with 8,710,347 (77.82%) votes cast in favour and 2,482,481 (22.18%) votes cast against.

4.   Reapproval of Company’s Shareholder Rights Plan

The Company’s shareholder rights plan was approved with 10,572,490 (94.46%) votes cast in favour and 620,338 (5.54%) votes cast against.

Final voting results on all matters voted on at the meeting will be filed under Haivision’s profile on SEDAR+ at www.sedarplus.ca.

About Haivision

Haivision is a leading global provider of mission-critical, real-time video streaming and visual collaboration solutions. Our connected cloud and intelligent edge technologies enable organizations globally to engage audiences, enhance collaboration, and support decision making. We provide high quality, low latency, secure, and reliable live video at a global scale. Haivision open sourced its award-winning SRT low latency video streaming protocol and founded the SRT Alliance to support its adoption. Awarded four Emmys® for Technology and Engineering from the National Academy of Television Arts and Sciences, Haivision continues to fuel the future of IP video transformation. Founded in 2004, Haivision is headquartered in Montreal and Chicago with offices, sales, and support located throughout the Americas, Europe, and Asia. Learn more at haivision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/haivision-announces-voting-results-from-2026-annual-meeting-of-shareholders-302752318.html

SOURCE Haivision Systems Inc.

Continue Reading

Trending